Cargando…

Three Drug Combinations in the Treatment of Fit Elderly Multiple Myeloma Patients

The multiple myeloma (MM) non transplant eligible (NTE) population is growing in line with the aging of the population in Western countries. Historically, this population has been known for having a greater risk of treatment related toxicity, and therefore drug development was slow and rather orient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gardeney, Hélène, Bobin, Arthur, Gruchet, Cécile, Sabirou, Florence, Lévy, Anthony, Nsiala, Laly, Cailly, Laura, Tomowiak, Cécile, Torregrosa, Jose, Moya, Niels, Hulin, Cyrille, Leleu, Xavier, Guidez, Stéphanie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694236/ https://www.ncbi.nlm.nih.gov/pubmed/33158277 http://dx.doi.org/10.3390/jcm9113554

Ejemplares similares

The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma
por: Bobin, Arthur, et al.
Publicado: (2020)

Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review Article
por: Bobin, Arthur, et al.
Publicado: (2021)

Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020
por: Bobin, Arthur, et al.
Publicado: (2020)

Hairy cell leukemia with isolated bone lesions
por: Cailly, Laura, et al.
Publicado: (2023)

Hodgkin lymphoma and female fertility: a multicenter study in women treated with doxorubicin, bleomycin, vinblastine, and dacarbazine
por: Machet, Antoine, et al.
Publicado: (2022)

Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma
por: Fouquet, Guillemette, et al.
Publicado: (2018)

Response to pneumococcal vaccination in multiple myeloma
por: Renaud, Loïc, et al.
Publicado: (2019)

Recent advances in the treatment of multiple myeloma: a brief review
por: Bobin, Arthur, et al.
Publicado: (2022)

30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma
por: Chacon, Aurelia, et al.
Publicado: (2023)

Role of IRF4 in resistance to immunomodulatory (IMid) compounds(®) in Waldenström’s macroglobulinemia
por: Bertrand, Elisabeth, et al.
Publicado: (2017)

Oral CHOP‐like chemotherapy in 60–80 years‐old patients with diffuse large B‐cell lymphoma
por: Guidez, Stephanie, et al.
Publicado: (2019)

Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma
por: Kendrick, Felicity, et al.
Publicado: (2017)

Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond
por: Podar, Klaus, et al.
Publicado: (2021)

Meningeal involvement in multiple myeloma
por: Laribi, Kamel, et al.
Publicado: (2015)

Choline PET/CT in Multiple Myeloma
por: Mesguich, Charles, et al.
Publicado: (2020)

All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study
por: Touzeau, Cyrille, et al.
Publicado: (2022)

Long‐term molecular remission in a patient with acute myeloid leukemia harboring a new NUP98‐LEDGF rearrangement
por: Gallego Hernanz, Maria Pilar, et al.
Publicado: (2019)

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab
por: Mikhael, Joseph, et al.
Publicado: (2021)

Safety Profile of Ibrutinib: An Analysis of the WHO Pharmacovigilance Database
por: Allouchery, Marion, et al.
Publicado: (2021)

Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?
por: Leleu, Xavier, et al.
Publicado: (2017)

Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk
por: Corre, Jill, et al.
Publicado: (2020)

Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study
por: Talbot, Alexis, et al.
Publicado: (2023)

Bone Marrow Microenvironment in Multiple Myeloma Progression
por: Manier, S., et al.
Publicado: (2012)

P930: ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB VS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 3 MAGNETISMM-5 STUDY, PART 2
por: Leleu, Xavier, et al.
Publicado: (2023)

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
por: Ludwig, Heinz, et al.
Publicado: (2020)

Front line treatment of elderly multiple myeloma in the era of novel agents
por: Venon, Marie-Dominique, et al.
Publicado: (2009)

P938: SURVIVAL OF PATIENTS WITH MULTIPLE MYELOMA IN THE GENERAL POPULATION BASED ON DATA FROM TWO FRENCH CANCER REGISTRIES
por: Hulin, Cyrille, et al.
Publicado: (2023)

Orientación escolar y profesional de los niños /
por: Cailly, Pierre
Publicado: (1977)

Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
por: Richardson, Paul G., et al.
Publicado: (2021)

An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment
por: Dimopoulos, Meletios A., et al.
Publicado: (2022)

COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
por: Ludwig, Heinz, et al.
Publicado: (2021)

Global Epigenetic Regulation of MicroRNAs in Multiple Myeloma
por: Zhang, Wenjing, et al.
Publicado: (2014)

Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel
por: Leleu, Xavier, et al.
Publicado: (2022)

Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe
por: Terpos, Evangelos, et al.
Publicado: (2022)

PB2090: SYSTEMATIC LITERATURE REVIEW OF PROGNOSTIC FACTORS FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Kumar, Shaji, et al.
Publicado: (2023)

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
por: Richardson, Paul G., et al.
Publicado: (2021)

Prospective Comparison of 18-FDG PET/CT and Whole-Body MRI with Diffusion-Weighted Imaging in the Evaluation of Treatment Response of Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant
por: Mesguich, Charles, et al.
Publicado: (2021)

Mass Spectrometry Imaging of Specialized Metabolites for Predicting Lichen Fitness and Snail Foraging
por: Gadea, Alice, et al.
Publicado: (2020)

A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial
por: Facon, Thierry, et al.
Publicado: (2019)

Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study
por: Kraeber-Bodéré, Françoise, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d7g731tbgkcaunkeul89lu9q6a